Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Seres Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of microbiome-based therapeutics designed to treat diseases by modulating the human microbiome. The company operates within the biotechnology and pharmaceutical research and development industries, with a historical emphasis on infectious diseases and a current strategic focus on oncology and immunology-related indications.
The company’s core competency lies in rationally designed, live biotherapeutic products derived from human microbiota. Seres gained industry recognition through the development and regulatory approval of VOWST, the first FDA-approved orally administered microbiota-based therapy for recurrent Clostridioides difficile infection. Founded in 2010, Seres emerged from microbiome research pioneered by its founders and early academic collaborators and has since evolved from a broad microbiome platform company into a more focused developer following portfolio restructuring and asset divestitures.
Business Operations
Seres operates primarily as a single reporting segment centered on biopharmaceutical research and development, generating revenue historically through product sales, collaboration agreements, and milestone-based payments. Following the divestiture of its commercial-stage asset, the company’s operations are now primarily focused on advancing early- and mid-stage clinical programs, with expenditures concentrated on R&D, clinical trials, and platform innovation.
The company develops proprietary consortia of bacterial strains manufactured using controlled fermentation and formulation technologies. Seres does not currently maintain large-scale commercial manufacturing operations and relies on third-party manufacturers and research partners. Its historical and ongoing collaborations include relationships with large healthcare and life sciences organizations, and it operates through wholly owned subsidiaries without material joint ventures disclosed in recent public filings.
Strategic Position & Investments
Seres’ strategic direction centers on applying microbiome therapeutics to oncology, particularly in combination with immune checkpoint inhibitors to improve cancer treatment outcomes. Growth initiatives include advancing pipeline candidates through clinical trials, refining its discovery platform, and selectively partnering programs to offset development costs.
A major strategic event was the sale of VOWST and related assets to Nestlé Health Science in 2024, which materially altered the company’s revenue profile and capital structure while allowing management to reallocate resources toward earlier-stage programs. The company does not report a diversified investment portfolio but continues to invest internally in next-generation microbiome science and translational research targeting immune-mediated diseases.
Geographic Footprint
Seres Therapeutics is headquartered in North America, with its principal offices in the United States. The company’s operations are primarily U.S.-based, encompassing corporate management, research oversight, and clinical development activities.
International exposure is largely indirect, occurring through global clinical trials, manufacturing partners, and prior commercial distribution arrangements for its approved product. While Seres does not maintain significant standalone international facilities, its technologies and intellectual property have global applicability, and its partnerships extend its operational influence into Europe and other major pharmaceutical markets.
Leadership & Governance
Seres is led by an executive team with experience in biotechnology development, regulatory strategy, and life sciences commercialization. The leadership emphasizes disciplined capital allocation, scientific rigor, and strategic focus following the company’s transition away from commercial operations.
Key executives include:
- Eric D. Shaff – President and Chief Executive Officer
- Joel Ronkin – Chief Financial Officer
- Eric D. Smith – Executive Vice President, Research and Development
- Noubar Afeyan – Chairman of the Board
The company was founded with the involvement of Noubar Afeyan through Flagship Pioneering, reflecting a governance philosophy centered on innovation-driven company building and long-term scientific value creation.